Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,432.10 23.56 0.14%
S&P 500 1,868.79 3.94 0.21%
NASDAQ 4,105.99 10.48 0.26%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

More than 30 Kenyan Children with Severe Spinal Disorders to Benefit from RTI Biologics’ Allograft Donation to CURE



  More than 30 Kenyan Children with Severe Spinal Disorders to Benefit from
  RTI Biologics’ Allograft Donation to CURE International

Business Wire

ALACHUA, Fla. -- May 30, 2013

RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and
other biologic implants, recently donated 35 bone allograft implants to
Lemoyne, Pa.-based CURE International. The demineralized bone matrix (DBM)
powder, illium strip tricortical and hemi femoral shaft will be used at
AIC-CURE International Children’s Hospital of Kenya in Kijabe, Kenya, to care
for more than 30 children with severe spinal disorders.

Patients at AIC-CURE International Children's Hospital of Kenya's mobile
clinic. (Photo: Business W ...

Patients at AIC-CURE International Children's Hospital of Kenya's mobile
clinic. (Photo: Business Wire)

According to Timothy Mead, M.D., global consultant for CURE International, the
allografts will be used to treat physically disabled,
economically-disadvantaged patients at CURE’s 30-bed orthopedic/pediatric
teaching hospital. The hospital provides care for children suffering from
conditions such as clubfoot, cleft lip and cleft palate, curvature of the
spine and disabilities stemming from polio, cerebral palsy, muscular dystrophy
and other congenital abnormalities. The donated implants will be used as part
of the treatment for patients suffering from tuberculosis, which often affects
their spine and other joints.

“Typically, children with severe spinal disorders will arrive at our mobile
clinic in an advanced state of the disease in which an entire vertebra or more
may have been eaten away and the spine is collapsing into severe kyphosis,”
said Mead. “The child may be unable to walk independently, they may have
difficulty controlling their bladder and bowels and all will have constant
back pain. The worst affected children are unable to move or feel their lower
limbs, which puts them at risk of developing pressure sores, infection and
death.”

CURE International surgeons working in Kenya have limited access to metal or
synthetic implants and, with small children in particular, there may be little
autograft available for the surgery. Allograft implants, such as those donated
by RTI, can be used to restore spinal alignment and fill the defect after
surgery.

“Recovery following the surgery is a slow process, but often, within a few
days, we see improvement,” said Mead. “Patients find that their back pain
disappears and smiles return to their faces.”

According to Mead, RTI’s donated implants will help more than 30 children in
Kenya—the total amount of children who undergo spinal reconstruction surgery
in one year at the hospital.

“As a global biologics company, RTI is honored to support the work of surgeons
like Dr. Mead through this donation to CURE International,” said Brian K.
Hutchison, RTI president and CEO. “We are grateful to be a part of the process
— from the generous gift of tissue donation to the hard work of the surgeon at
implantation — of providing these safe, biologic implants that will help
restore life for these children in Kenya.”

Allografts are used as an alternative to synthetic and metal implants.
However, unlike synthetic or metal implants, allografts are a natural and
biocompatible scaffold, allowing the recipient’s body to remodel it into his
or her own tissue over time. Using allograft tissue rather than an autograft
eliminates a second surgical site, allowing the recipient to avoid additional
pain, risk and a possibly longer hospital stay. In addition, in some cases, it
is not possible to obtain an autograft, so allografts are a natural solution.

RTI uses stringent donor screening, laboratory testing and proprietary,
validated sterilization processes to ensure patients’ safety. These redundant
safeguards provide the highest level of confidence that patients will receive
safe, high quality tissue. RTI honors the gift of tissue donation by treating
the tissue with respect, by finding new ways to use the tissue to help
patients and by helping as many patients as possible from each donation.

About CURE International

CURE International is the largest provider of reconstructive surgery to
disabled children in the developing world and operates hospitals and programs
in 29 nations. Since opening the doors of its first surgical teaching hospital
in Kijabe, Kenya in 1998, CURE’s focus on bringing healing to developing
nations has resulted in more than 2 million patient visits and over 147,000
surgeries to correct physically disabling conditions. CURE has also trained
more than 6,600 medical professionals, raising the standard of care in the
countries where it operates.

The AIC-CURE International Children's Hospital in Kijabe serves approximately
8,000 children and performs approximately 2,500 surgeries each year. The
hospital also operates mobile clinics that travel to remote regions to provide
follow-up care and identify children who can be treated at the hospital. To
learn more, visit www.cure.org.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for
surgeries around the world with a commitment to advancing science, safety and
innovation. RTI prepares human donated tissue and animal tissue for
transplantation through extensive testing and screening, precision shaping and
using proprietary, validated processes. These allograft and xenograft implants
are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for
biologics – from being the first company to offer precision-tooled bone
implants and assembled technology to maximize each gift of donation, to
inventing validated sterilization processes that include viral inactivation
steps. These processes — BioCleanse^®, Tutoplast^® and Cancelle^® SP DBM —
have a combined record of more than five million implants sterilized with zero
incidence of implant-associated infection. These processes have been validated
by tissue type to inactivate or remove viruses, bacteria, fungi and spores
from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with
international locations in Germany and France. The company is accredited by
the American Association of Tissue Banks in the United States and is a member
of AdvaMed.

Editor’s Note: Photos of AIC-CURE International Children’s Hospital of Kenya
in Kijabe, Kenya, are available upon request.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130530006408/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50643312&lang=en

Contact:

RTI Biologics Inc.
Jenny Highlander, APR, 386-418-8888, ext. 4149
Manager, Corporate Communications
jhighlander@rtix.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement